Compare GROV & MREO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GROV | MREO |
|---|---|---|
| Founded | 2016 | 2015 |
| Country | United States | United Kingdom |
| Employees | 415 | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.4M | 67.5M |
| IPO Year | N/A | 2017 |
| Metric | GROV | MREO |
|---|---|---|
| Price | $1.34 | $0.34 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $1.60 | ★ $3.13 |
| AVG Volume (30 Days) | 75.4K | ★ 1.5M |
| Earning Date | 03-05-2026 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 16.67 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $500,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.81 | $6,363.05 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.02 | $0.20 |
| 52 Week High | $1.66 | $2.94 |
| Indicator | GROV | MREO |
|---|---|---|
| Relative Strength Index (RSI) | 50.56 | 34.82 |
| Support Level | $1.29 | $0.20 |
| Resistance Level | $1.46 | $0.42 |
| Average True Range (ATR) | 0.07 | 0.03 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 70.59 | 22.62 |
Grove Collaborative Holdings Inc is engaged in providing consumer products. It offers Cleaning accessories, Home and Pantry, Personal care products, Pets supplements and Other products. It is a sustainability oriented consumer products generator. It use connection with consumers to create and curate authentic, disruptive brands and products. Company builds natural products that perform as well as, many consumer packaged goods (CPG) brands (both conventional and natural), while being healthier for consumers and the planet.
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat primarily for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).